Introduction
GLP-1 agonists have become one of the most important areas of modern metabolic medicine. Originally developed primarily for the management of type 2 diabetes, these therapies have expanded into obesity and weight-management applications, creating significant demand for innovative medicines, manufacturing capacity, and next-generation treatment options.
The market includes established pharmaceutical companies with commercially available products as well as biotechnology companies developing new GLP-1-based therapies. Products and pipelines now include injectable medicines, oral formulations, combination therapies, and next-generation molecules designed to improve efficacy, convenience, tolerability, and patient access.
According to the MarketsandMarkets report, the global GLP-1 agonists market was valued at USD 53.74 billion in 2024 and is projected to reach USD 170.75 billion by 2033, representing a CAGR of approximately 13.0% from 2025 to 2033. The report attributes market expansion to the increasing prevalence of obesity and type 2 diabetes, expanded indications, manufacturing investments, and continued development of new GLP-1 therapies.
This article explores major GLP-1 agonist manufacturers, their products and development strategies, and the trends shaping the pharmaceutical market.
What Are GLP-1 Agonists?
GLP-1, or glucagon-like peptide-1, is a hormone involved in glucose regulation, appetite, and digestion. GLP-1 receptor agonists are medicines that activate the GLP-1 receptor and can help improve blood glucose control while also influencing appetite and body weight.
Some therapies in this broader market are based directly on GLP-1 receptor agonism, while others, such as tirzepatide, act on multiple incretin pathways. For this reason, the commercial market is often discussed more broadly as the GLP-1 or incretin market.
These therapies have become important in the treatment of metabolic conditions because of their effects on blood glucose and body weight. Some products have also demonstrated cardiovascular or other health benefits in specific patient populations.
Download the PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218746186
Leading GLP-1 Agonist Manufacturers
1. Novo Nordisk
Novo Nordisk is one of the most prominent GLP-1 manufacturers globally. The Danish pharmaceutical company has extensive experience in diabetes and metabolic disease and has developed several major GLP-1-based medicines.
Its portfolio includes Ozempic and Wegovy, which contain semaglutide, as well as Rybelsus, an oral semaglutide product. Ozempic is primarily associated with type 2 diabetes treatment, while Wegovy is used for chronic weight management in approved markets.
MarketsandMarkets identifies Novo Nordisk as a leading player in the GLP-1 agonists market. Its report states that Ozempic accounted for the largest market share among the products analyzed, supported by adoption in type 2 diabetes, geographic availability, and strong brand recognition.
Novo Nordisk’s scale also extends to manufacturing. The company has made substantial investments to expand production capacity as demand for GLP-1 therapies has increased.
2. Eli Lilly and Company
Eli Lilly and Company is another major manufacturer in the GLP-1 and incretin market.
Its key products include Mounjaro and Zepbound, both based on tirzepatide. Tirzepatide activates both the GIP and GLP-1 receptors, distinguishing it mechanistically from medicines that target only the GLP-1 receptor.
Mounjaro is used for type 2 diabetes in approved markets, while Zepbound is indicated for chronic weight management and certain related conditions depending on the market and regulatory approval.
Novo Nordisk and Eli Lilly have become the two most important companies in the global GLP-1 market. Novo Nordisk’s own annual-report materials describe the two companies as the leading participants by GLP-1 market share.
The competition between the companies is increasingly extending beyond injectable therapies into oral medicines and next-generation obesity treatments.
Request Sample Pages @https://www.marketsandmarkets.com/requestsampleNew.asp?id=218746186
3. Sanofi
Sanofi is another major pharmaceutical company included by MarketsandMarkets among key participants in the GLP-1 agonists market.
Sanofi has a broad presence in diabetes and other therapeutic areas. Its participation in the GLP-1 ecosystem illustrates the interest of large pharmaceutical companies in metabolic disease and the evolving opportunities around incretin-based medicines.
As the market develops, manufacturers are increasingly evaluating new formulations, combinations, and approaches that could complement existing GLP-1 therapies.
4. Boehringer Ingelheim
Boehringer Ingelheim is developing next-generation metabolic therapies and is highlighted by MarketsandMarkets as an emerging leader in the market.
One of its important programs is survodutide, a molecule being investigated as a dual GLP-1/glucagon receptor agonist. MarketsandMarkets identifies survodutide as being in Phase 3 development and highlights Boehringer Ingelheim’s position as an emerging leader in the competitive landscape.
The development of multi-receptor agonists demonstrates how manufacturers are moving beyond conventional GLP-1 approaches to potentially address multiple aspects of metabolic disease.
5. Innovent Biologics
Innovent Biologics is a China-based biopharmaceutical company included among the key players identified by MarketsandMarkets.
The company is participating in the expanding metabolic-disease market and illustrates the increasing role of Chinese pharmaceutical and biotechnology companies in the development of GLP-1 and related therapies.
China represents an important growth opportunity for metabolic medicines because of its large population and significant burden of diabetes and obesity.
6. Sun Pharmaceutical Industries
Sun Pharmaceutical Industries is one of India’s largest pharmaceutical companies and is listed by MarketsandMarkets among the major companies in the GLP-1 agonists market.
India is an important market for diabetes therapies, and pharmaceutical manufacturers in the country are increasingly interested in advanced metabolic medicines.
The development and commercialization of GLP-1 therapies in India could become increasingly important as demand for effective diabetes and obesity treatments grows.
7. Biocon
Biocon is another Indian biotechnology and pharmaceutical company identified by MarketsandMarkets as a key participant in the GLP-1 market.
Biocon’s presence is particularly relevant to the broader discussion surrounding biosimilars and more affordable access to complex biologic medicines.
As patents and regulatory exclusivities evolve, biosimilar and follow-on products may become increasingly important in expanding access to GLP-1-related therapies.
8. Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is also included among the key companies identified in the MarketsandMarkets report.
The company’s inclusion reflects the growing participation of Indian pharmaceutical manufacturers in metabolic healthcare and the potential development of more accessible GLP-1 treatment options.
Other Companies Developing GLP-1 and Next-Generation Therapies
The GLP-1 market extends beyond established commercial products. Several biotechnology companies are working on new molecules and approaches.
MarketsandMarkets identifies companies including Pegbio, Structure Therapeutics, Viking Therapeutics, Amgen, Altimmune, Teva Pharmaceuticals, and Hansoh Pharmaceutical Group among the key players in the broader market.
These companies are pursuing different strategies, including oral therapies, multi-receptor agonists, long-acting medicines, and other approaches to weight management and metabolic disease.
For example, Structure Therapeutics is developing oral small-molecule approaches to metabolic disease, while Viking Therapeutics is developing therapies targeting metabolic and obesity-related conditions.
This competitive pipeline is important because the next stage of GLP-1 development may not simply involve producing more versions of existing injections. Companies are increasingly competing on convenience, dosing, weight-loss efficacy, tolerability, manufacturing efficiency, and broader metabolic benefits.
Major GLP-1 Products
The GLP-1 agonist market includes several important products and pipeline therapies.
MarketsandMarkets segments the market by products including Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Trulicity, Orforglipron, CagriSema, Survodutide, Retatrutide, semaglutide biosimilars, and other GLP-1 biosimilars.
These products represent different mechanisms, formulations, and stages of commercial or clinical development.
Semaglutide
Semaglutide is one of the most commercially important molecules in the market. It is used in products such as Ozempic, Wegovy, and Rybelsus.
Its availability in both injectable and oral formulations demonstrates the industry’s movement toward different delivery methods.
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. Its products Mounjaro and Zepbound have become important competitors in diabetes and obesity treatment.
The success of tirzepatide has also encouraged pharmaceutical companies to explore additional multi-target approaches.
Next-Generation Molecules
The pipeline increasingly includes molecules designed to activate more than one metabolic pathway. These approaches could potentially produce stronger effects or address additional aspects of metabolic disease.
Examples identified in the MarketsandMarkets market segmentation include survodutide, retatrutide, and CagriSema.
Oral GLP-1 Drugs and Manufacturing Trends
One of the most important opportunities in the GLP-1 market is the development of oral medicines.
Injectable treatments can be highly effective, but some patients may prefer tablets because of convenience, familiarity, or concerns about injections. MarketsandMarkets identifies increasing research into oral GLP-1 therapies as a significant market opportunity.
The development of effective oral formulations could expand the patient population and change the competitive landscape.
Manufacturing is another major factor. Growing demand has encouraged pharmaceutical companies to invest in production facilities, active pharmaceutical ingredient capacity, fill-finish operations, and supply-chain infrastructure.
According to MarketsandMarkets, expanding manufacturing capacity is a major driver of the GLP-1 agonists market because manufacturers need to increase production to meet rising global demand.
Why Manufacturing Capacity Matters
The success of a GLP-1 therapy depends on more than clinical efficacy. Manufacturers must be able to produce medicines consistently at large scale while maintaining quality and regulatory compliance.
High-demand medicines can place significant pressure on pharmaceutical supply chains. Manufacturers therefore need reliable sources of active pharmaceutical ingredients, specialized production equipment, quality-control systems, packaging capacity, and distribution networks.
Investments in manufacturing can help pharmaceutical companies increase supply and prepare for future product launches.
Key Factors Driving the GLP-1 Market
Several factors are contributing to the expansion of the market.
Rising Obesity and Diabetes Rates
The global prevalence of obesity and type 2 diabetes continues to create demand for effective metabolic treatments. MarketsandMarkets identifies these conditions as major drivers of GLP-1 adoption.
Expanding Indications
As clinical research continues, pharmaceutical companies are investigating whether GLP-1-based therapies can be used in additional metabolic and cardiovascular settings.
Expansion into new indications can increase the potential patient population.
New Drug Delivery Technologies
Oral formulations and other delivery technologies may make treatment more convenient and potentially broaden adoption.
Increasing Manufacturing Investment
Pharmaceutical companies are investing in manufacturing capacity to address high demand and prepare for continued market growth.
Challenges for GLP-1 Manufacturers
Despite the strong growth outlook, manufacturers face several challenges.
Cost and Payer Controls
The high cost of some GLP-1 therapies has created challenges for healthcare systems, insurers, and patients. MarketsandMarkets identifies stringent cost and payer controls as a significant market restraint.
Insurers and healthcare systems may introduce eligibility criteria, formulary restrictions, or other measures to manage spending.
Supply Chain Pressure
Rapid demand growth can create pressure on manufacturing and distribution networks. Companies must continuously expand capacity while maintaining product quality.
Counterfeit and Unauthorized Products
Counterfeit and unauthorized GLP-1 products create safety, regulatory, and brand risks. MarketsandMarkets identifies counterfeit and compounded GLP-1 products as an important challenge for the market.
Patients should obtain prescription medicines through legitimate, regulated healthcare and pharmacy channels.
Tolerability and Persistence
Like other medicines, GLP-1 therapies can have adverse effects and may not be suitable for every patient. Manufacturers are therefore working on formulations and molecules designed to improve tolerability and treatment persistence.
Future Outlook for GLP-1 Agonist Manufacturers
The future of the GLP-1 market is likely to involve greater competition between established pharmaceutical companies and emerging biotechnology firms.
The next generation of products may include:
- Oral GLP-1 therapies
- Dual- and multi-receptor agonists
- Combination treatments
- Long-acting formulations
- Biosimilar and follow-on products
- Therapies targeting obesity-related complications
- Medicines designed to improve tolerability
- More personalized approaches to metabolic disease management
MarketsandMarkets forecasts substantial growth in the overall market through 2033, with North America currently representing a major market while Asia Pacific is expected to experience strong growth.
The competitive environment is also changing rapidly. Novo Nordisk and Eli Lilly remain the leading commercial forces, but a growing group of pharmaceutical and biotechnology companies is working to introduce new mechanisms and formulations.
Conclusion
GLP-1 agonist manufacturers are at the center of a rapidly expanding pharmaceutical market. Companies such as Novo Nordisk and Eli Lilly currently have major commercial positions, while Boehringer Ingelheim, Sanofi, Innovent, Sun Pharmaceutical Industries, Biocon, Glenmark Pharmaceuticals, and numerous biotechnology companies are contributing to the broader competitive landscape.
The market is evolving from a focus on traditional injectable diabetes therapies toward a broader ecosystem that includes obesity treatment, oral medicines, combination therapies, next-generation multi-receptor agonists, and biosimilars.
According to MarketsandMarkets, the global GLP-1 agonists market is projected to grow from USD 53.74 billion in 2024 to USD 170.75 billion by 2033.
As demand continues to increase, the ability of manufacturers to scale production, develop innovative therapies, maintain quality, and expand patient access will be central to the future of the GLP-1 industry.